恶唑烷酮类抗生素U-100592和U-100766对金黄色葡萄球菌和凝固酶阴性葡萄球菌的体外活性
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
作者信息
Jorgensen J H, McElmeel M L, Trippy C W
机构信息
Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7750, USA.
出版信息
Antimicrob Agents Chemother. 1997 Feb;41(2):465-7. doi: 10.1128/AAC.41.2.465.
Abstract
U-100592 and U-100766 are closely related antibiotics of the oxazolidinone class. Their in vitro activities were determined against 100 isolates of Staphylococcus aureus and 100 isolates of coagulase-negative Staphylococcus species by broth and agar dilution test methods. The MICs of both compounds by either test method at which 50 and 90% of isolates are inhibited were 2 and 4 micrograms/ml, respectively, for S. aureus and 1 to 2 micrograms/ml for coagulase-negative staphylococci. Time-kill assay with selected strains indicated a primarily bacteriostatic effect against staphylococci.
摘要
U - 100592和U - 100766是密切相关的恶唑烷酮类抗生素。通过肉汤稀释法和琼脂稀释法测定了它们对100株金黄色葡萄球菌和100株凝固酶阴性葡萄球菌的体外活性。两种化合物在两种测试方法中对50%和90%分离株产生抑制作用时的最低抑菌浓度（MIC），对金黄色葡萄球菌分别为2微克/毫升和4微克/毫升，对凝固酶阴性葡萄球菌为1至2微克/毫升。对选定菌株的时间 - 杀菌试验表明，其对葡萄球菌主要起抑菌作用。
相似文献
1
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
Antimicrob Agents Chemother. 1997 Feb;41(2):465-7. doi: 10.1128/AAC.41.2.465.
2
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
3
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
4
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
5
In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
Antimicrob Agents Chemother. 2002 Aug;46(8):2662-4. doi: 10.1128/AAC.46.8.2662-2664.2002.
6
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
7
In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.
J Antimicrob Chemother. 2012 Jan;67(1):167-9. doi: 10.1093/jac/dkr403. Epub 2011 Sep 27.
8
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
J Antimicrob Chemother. 1999 Apr;43(4):569-73. doi: 10.1093/jac/43.4.569.
9
Linezolid resistance in coagulase-negative staphylococci.
J Antimicrob Chemother. 2006 Oct;58(4):898-9; author reply 899-900. doi: 10.1093/jac/dkl271. Epub 2006 Jul 19.
10
In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
Antimicrob Agents Chemother. 1996 Jul;40(7):1745-7. doi: 10.1128/AAC.40.7.1745.
引用本文的文献
1
Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study.
Curr Ther Res Clin Exp. 2007 Jan;68(1):23-31. doi: 10.1016/j.curtheres.2007.02.001.
2
Newer antibacterial drugs for a new century.
Expert Opin Investig Drugs. 2010 Feb;19(2):215-34. doi: 10.1517/13543780903505092.
3
Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.
Antimicrob Agents Chemother. 2009 Mar;53(3):1142-8. doi: 10.1128/AAC.00775-08. Epub 2008 Dec 15.
4
A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?
Can J Infect Dis. 2001 Nov;12(6):379-90. doi: 10.1155/2001/260651.
5
Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci.
J Clin Microbiol. 2007 Sep;45(9):2917-22. doi: 10.1128/JCM.00913-07. Epub 2007 Jul 18.
6
In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Antimicrob Agents Chemother. 2003 Jun;47(6):1902-6. doi: 10.1128/AAC.47.6.1902-1906.2003.
7
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.
Antimicrob Agents Chemother. 2003 Jan;47(1):418-20. doi: 10.1128/AAC.47.1.418-420.2003.
8
Vancomycin resistance in staphylococci.
Clin Microbiol Rev. 2002 Jul;15(3):430-8. doi: 10.1128/CMR.15.3.430-438.2002.
9
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.
Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13. doi: 10.1128/AAC.44.12.3408-3413.2000.
10
In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori.
Antimicrob Agents Chemother. 2000 Jul;44(7):1977-9. doi: 10.1128/AAC.44.7.1977-1979.2000.
本文引用的文献
1
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
2
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
3
Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.
N Engl J Med. 1994 Apr 28;330(17):1247-51. doi: 10.1056/NEJM199404283301725.
4
Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.
Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. doi: 10.1128/AAC.31.11.1791.
5
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.
J Antimicrob Chemother. 1988 Jun;21(6):721-30. doi: 10.1093/jac/21.6.721.
6
In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.
Antimicrob Agents Chemother. 1988 Jan;32(1):150-2. doi: 10.1128/AAC.32.1.150.
7
Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.
Antimicrob Agents Chemother. 1988 Aug;32(8):1218-22. doi: 10.1128/AAC.32.8.1218.
8
The crisis in antibiotic resistance.
Science. 1992 Aug 21;257(5073):1064-73. doi: 10.1126/science.257.5073.1064.
9
Epidemiology of drug resistance: implications for a post-antimicrobial era.
Science. 1992 Aug 21;257(5073):1050-5. doi: 10.1126/science.257.5073.1050.
Zotero 插件